ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+4.74%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$485M
AUM Growth
+$485M
(-19%)
Cap. Flow
-$74.8M
Cap. Flow
% of AUM
-15.41%
Top 10 Holdings %
Top 10 Hldgs %
49.77%
Holding
309
New
41
Increased
54
Reduced
66
Closed
104
Top Buys
| 1 |
Inhibikase Therapeutics
IKT
|
$16.6M |
| 2 |
Zai Lab
ZLAB
|
$13.4M |
| 3 |
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
$10.1M |
| 4 |
ABVX
Abivax
ABVX
|
$7.26M |
| 5 |
AVR
Anteris Technologies Global Corp. Common Stock
AVR
|
$5.88M |
Top Sells
| 1 |
Royalty Pharma
RPRX
|
$26.7M |
| 2 |
Cytokinetics
CYTK
|
$23.4M |
| 3 |
BridgeBio Pharma
BBIO
|
$21.1M |
| 4 |
Ascendis Pharma
ASND
|
$12.4M |
| 5 |
Immunovant
IMVT
|
$8.53M |
Sector Composition
| 1 | Healthcare | 80.2% |
| 2 | Financials | 3.47% |
| 3 | Communication Services | 1.36% |
| 4 | Utilities | 0.04% |
| 5 | Energy | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Roivant Sciences
ROIV
$8.15B
| $41.5M | 8.3% | 3,508,694 +483,244 | +16% | +$5.72M |
|
2
Protagonist Therapeutics
PTGX
$3.67B
| $39.4M | 7.87% | 1,020,333 +39,038 | +4% | +$1.51M |
|
3
Alpha Architect 1-3 Month Box ETF
BOXX
$7.91B
| $35.9M | 7.17% | 325,450 +2,068 | +0.6% | +$228K |
|
|
4
Zai Lab
ZLAB
$3.68B
| $27.4M | 5.47% | 1,045,837 +513,383 | +96% | +$13.4M |
|
|
5
Immunovant
IMVT
$2.56B
| $19.5M | 3.9% | 787,478 -344,229 | -30% | -$8.53M |
|
|
6
Cytokinetics
CYTK
$4.23B
| $19.5M | 3.89% | 414,209 -496,973 | -55% | -$23.4M |
|
|
7
BridgeBio Pharma
BBIO
$9.89B
| $18.6M | 3.72% | 678,857 -769,613 | -53% | -$21.1M |
|
|
8
Inhibikase Therapeutics
IKT
$134M
| $16.6M | 3.31% | +5,103,005 | New | +$16.6M |
|
|
9
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$42.1B
| $12M | 2.41% | 131,786 +110,000 | +505% | +$10.1M |
|
|
ABVX
10
Abivax
ABVX
$6.12B
| $11.1M | 2.21% | 1,513,393 +991,781 | +190% | +$7.26M |
|
11
Mineralys Therapeutics
MLYS
$1.03B
| $10.4M | 2.07% | 841,541 +112,140 | +15% | +$1.38M |
|
|
12
Ascendis Pharma
ASND
$11.8B
| $9.83M | 1.96% | 71,402 -90,000 | -56% | -$12.4M |
|
|
PCSC
13
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $7.64M | 1.53% | 750,000 | – | – |
|
14
Revolution Medicines
RVMD
$7.1B
| $7.44M | 1.49% | 170,000 +125,649 | +283% | +$5.5M |
|
15
Rezolute
RZLT
$619M
| $6.66M | 1.33% | 1,359,208 -212,497 | -14% | -$1.04M |
|
|
EDR
16
DELISTED
Endeavor Group Holdings, Inc.
EDR
| $6.59M | 1.32% | 210,729 +87,922 | +72% | +$2.75M |
|
17
CG Oncology
CGON
$2.04B
| $6.19M | 1.24% | 215,750 +72,646 | +51% | +$2.08M |
|
|
AVR
18
Anteris Technologies Global Corp. Common Stock
AVR
$145M
| $5.88M | 1.17% | +1,052,968 | New | +$5.88M |
|
|
AAM
19
AA Mission Acquisition Corp.
AAM
$462M
| $5.66M | 1.13% | 560,199 -450,000 | -45% | -$4.55M |
|
20
Xencor
XNCR
$580M
| $5.39M | 1.08% | 234,607 -107,655 | -31% | -$2.47M |
|
21
Zura Bio
ZURA
$133M
| $5.19M | 1.04% | 2,077,251 -1,693,398 | -45% | -$4.23M |
|
22
Arbutus Biopharma
ABUS
$711M
| $5.08M | 1.02% | 1,554,802 -534,519 | -26% | -$1.75M |
|
|
OACCU
23
Oaktree Acquisition Corp. III Life Sciences Unit
OACCU
| $5.07M | 1.01% | +500,000 | New | +$5.07M |
|
24
Sarepta Therapeutics
SRPT
$1.78B
| $4.86M | 0.97% | 40,002 +32,902 | +463% | +$4M |
|
25
Sanofi
SNY
$121B
| $4.8M | 0.96% | +99,600 | New | +$4.8M |
|